Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in GH Secreting Pituitary Adenomas
NCT03309319Unknown
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rosiglitazone in growth hormone–secreting pituitary adenoma (GHPA). Primary endpoints: Growth hormone at 6 months, Insulin like growth factor 1 at 6 months and 1 more. Status: unknown.
02
Drugs
rosiglitazone
03
Conditions
growth hormone–secreting pituitary adenoma (GHPA)
Beyond the preview
Go deeper on NCT03309319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309319.